Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia

Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia

(2014) S. P. Treon et al.   BLOOD

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)

(2013) M. A. Dimopoulos et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

(2013) D. Siegel et al.   HAEMATOLOGICA

Severe Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma: A Case Report and Review of the Literature

(2012) Margarita Bockorny et al.   ACTA HAEMATOLOGICA

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop

(2012) Roger G. Owen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemia

(2011) Steven P. Treon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen

(2011) Steven P. Treon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

(2011) A. Sacco et al.   CLINICAL CANCER RESEARCH

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   AMERICAN JOURNAL OF HEMATOLOGY

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

(2010) Agathoclis Agathocleous et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase II Trial of Weekly Bortezomib in Combination With Rituximab in Relapsed or Relapsed and Refractory Waldenström Macroglobulinemia

(2010) Irene M. Ghobrial et al.   JOURNAL OF CLINICAL ONCOLOGY

Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors

(2009) E. B. Golden et al.   BLOOD

International prognostic scoring system for Waldenstrom macroglobulinemia

(2009) P. Morel et al.   BLOOD

How I treat Waldenstrom macroglobulinemia

(2009) S. P. Treon   BLOOD

IgA and IgG hypogammaglobulinemia in Waldenstrom's macroglobulinemia

(2009) Z. R. Hunter et al.   HAEMATOLOGICA

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180

(2009) Steven P. Treon et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia

(2008) S. P. Treon et al.   BLOOD

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY